| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_875861f3a625de7c6408a9b49f0b680d |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 |
| filingDate |
2021-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_358ecbb7a51fada0d33e764d5f897914
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04e83f7b3eef2a31de45a775f1128eef |
| publicationDate |
2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2021088583-A |
| titleOfInvention |
Emulsion containing NK-1 receptor antagonist |
| abstract |
PROBLEM TO BE SOLVED: To provide an emulsion containing an NK-1 receptor antagonist. Disclosed herein are novel pharmaceutical formulations of neurokinin-1 (NK-1) receptor antagonists suitable for parenteral administration, including intravenous administration. Also included is a formulation containing both an NK-1 receptor antagonist and sodium dexamethasone phosphate. The pharmaceutical formulation is a stable oil-in-water emulsion for the parenteral treatment of vomiting (emesis) and is particularly useful for the treatment of subjects undergoing highly emetic cancer chemotherapy. [Selection diagram] None |
| priorityDate |
2021-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |